Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:IBRX

ImmunityBio Q3 2026 Earnings Date & Estimates

ImmunityBio logo
$8.29 +0.34 (+4.28%)
Closing price 11/3/2026 04:00 PM Eastern
Extended Trading
$8.35 +0.06 (+0.66%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ImmunityBio in Q3 2026

ImmunityBio is expected to post earnings of -$0.07 per share on revenue of $59.23 million. In the same quarter a year earlier ImmunityBio reported -$0.0711 per share on revenue of $32.06 million. ImmunityBio last reported on August 4, 2026, posting -$0.22 per share and missing the -$0.08 consensus estimate. ImmunityBio has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.07
Expected Revenue
$59.23 million
Prior-Year EPS
-$0.0711
Prior-Year Revenue
$32.06 million
Expected Revenue Growth
+84.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.22 (Missed by -$0.14)
Last Quarter Revenue
$51.24 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

ImmunityBio Q3 2026 Earnings FAQ

ImmunityBio (NASDAQ:IBRX) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

ImmunityBio's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ImmunityBio to post earnings of -$0.07 per share for Q3 2026.

The consensus revenue estimate for ImmunityBio is $59.23 million for Q3 2026.

ImmunityBio Earnings Headlines

ImmunityBio Inc Ordinary Shares IBRX
November 3 at 2:19 AM  |  morningstar.comM
IBRX Stock Climbs Overnight: Founder Calls Sepsis Push ‘Unstoppable’ As Trials Near — Teases NantX After Crypto Heist
November 3 at 2:19 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ibrx-stock-climbs-overnight-founder-044415361.html
U.S. Army Advances 75-Year Rare Earth Deal With Nasdaq Firm
The Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just signed a term sheet for a potential 75-year agreement with the US Army. The proposed deal would let the company build and operate a rare earth processing facility on an active military base, with the Army getting first right to production. New Pentagon restrictions on Chinese-origin rare earth magnets take effect January 1, 2027. The company's mine-to-magnet platform covers feedstock agreements, processing, metallization, and downstream manufacturing, with commercial output targeted for 2027.tc pixel
 |  The Tomorrow Investor (Ad)
SLS, IOVA, IBRX slump in October as biotech stocks hold steady: Virginia pension fund raised stakes in all 3
October 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/sls-iova-ibrx-slump-in-october-as-biotech-stocks-hold-steady-virginia-pension-fund-raised-stakes-in-all-3/ar-AA2go2jw
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
October 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ibrx-stock-rises-overnight-jim-071451209.html
ImmunityBio (IBRX): November ANKTIVA Trial Results Could Support Expanded FDA Filing?
October 22, 2026  |  rttnews.comhttps://www.rttnews.com/3701856/immunitybio-ibrx-november-anktiva-trial-results-could-support-expanded-fda-filing.aspx
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In the United States, Anktiva is approved for use with Bacillus Calmette-Guérin in certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating Anktiva and related therapies in additional cancer indications and treatment combinations.

The company’s broader pipeline includes investigational therapies intended to support cancer immunotherapy, cellular immune responses and vaccine development. ImmunityBio was formed through the combination of ImmunityBio and NantKwest, completed in 2021, bringing together complementary immunotherapy platforms. The company is headquartered in California and was founded by Patrick Soon-Shiong, who serves as its executive chairman and has played a central role in its scientific and corporate direction.

View ImmunityBio Profile
Earnings Tools